Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Molecular Identity Developer Eli Lilly Brand Names Mounjaro (diabetes), Zepbound (obesity) Mechanism Dual GLP-1 and GIP receptor agonist FDA Status Approved (2022 diabetes, 2023 obesity) Administration Weekly subcutaneous GIP Receptor Pathway The GIP receptor activation in Tirzepatide provides different metabolic effects than glucagon: Incretin enhancement: GIP augments GLP-1's insulin-related signaling Adipose tissue effects: GIP receptor expression in fat tissue documented Tolerability profile: Some research suggests GIP may moderate GI effects Synergistic incretin signaling: Two incretin pathways vs
Some of the most well-known ones include: GLP-1 receptor agonists (e.g., semaglutide) Improve blood sugar control and support weight management
Focusing on the synergistic effect of exosomes and glutathione.The two ingredients stabilised by lipocapsule technology reach every corner of the skins stratum corneum
For a sensitive peptide formulation, it does
US$ 26.91
US$ 28.21
US$ 27.86
US$ 21.43
US$ 23.55
US$ 23.44
US$ 27.95
US$ 27.49
US$ 29.14
US$ 25.58